CN109843883A - 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途 - Google Patents

作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途 Download PDF

Info

Publication number
CN109843883A
CN109843883A CN201780044487.5A CN201780044487A CN109843883A CN 109843883 A CN109843883 A CN 109843883A CN 201780044487 A CN201780044487 A CN 201780044487A CN 109843883 A CN109843883 A CN 109843883A
Authority
CN
China
Prior art keywords
base
phenyl
pyridine
methyl
azetidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780044487.5A
Other languages
English (en)
Other versions
CN109843883B (zh
Inventor
张文燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Longbotai Pharmaceutical Co ltd
Original Assignee
Tianjin Longbogene Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Longbogene Pharmaceutical Co ltd filed Critical Tianjin Longbogene Pharmaceutical Co ltd
Publication of CN109843883A publication Critical patent/CN109843883A/zh
Application granted granted Critical
Publication of CN109843883B publication Critical patent/CN109843883B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

公开了一类作为选择性JAK抑制剂化合物，及其异构体、溶剂合物、或其药学上可接受的盐，其中：(A)、R、R1、n的定义详见说明书。此外，还公开了以该化合物、及其盐类为活性成分的药物，及其在制备治疗免疫系统疾病、类风湿关节炎、肿瘤等与JAK相关靶点疾病的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (5)

  1. PCT国内申请，权利要求书已公开。
CN201780044487.5A 2016-07-26 2017-07-25 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途 Active CN109843883B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016105907917 2016-07-26
CN201610590791 2016-07-26
CN201710037675 2017-01-19
CN2017100376757 2017-01-19
PCT/CN2017/094254 WO2018019223A1 (zh) 2016-07-26 2017-07-25 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途

Publications (2)

Publication Number Publication Date
CN109843883A true CN109843883A (zh) 2019-06-04
CN109843883B CN109843883B (zh) 2022-01-14

Family

ID=61015611

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780044487.5A Active CN109843883B (zh) 2016-07-26 2017-07-25 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途
CN201780044794.3A Active CN109790158B (zh) 2016-07-26 2017-07-25 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780044794.3A Active CN109790158B (zh) 2016-07-26 2017-07-25 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途

Country Status (6)

Country Link
US (2) US11414413B2 (zh)
EP (2) EP3492468B1 (zh)
JP (2) JP6978097B2 (zh)
KR (2) KR102492378B1 (zh)
CN (2) CN109843883B (zh)
WO (2) WO2018019223A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843883B (zh) 2016-07-26 2022-01-14 苏州隆博泰药业有限公司 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途
WO2020038457A1 (zh) * 2018-08-23 2020-02-27 珠海联邦制药股份有限公司 作为JAK抑制剂的[1，2，4]三唑并[1，5-a]吡啶类化合物及其应用
CN111620873B (zh) * 2019-02-28 2021-12-28 沈阳药科大学 一类含哌啶的吡咯并[2,3-d]嘧啶衍生物及其制备和用途
CN110028509B (zh) * 2019-05-27 2020-10-09 上海勋和医药科技有限公司 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途
KR20220127900A (ko) * 2020-02-13 2022-09-20 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 Jak 키나아제 관련 질병의 치료를 위한 약물의 제조에 있어서 jak 억제제의 용도
US20230091250A1 (en) * 2020-02-21 2023-03-23 Zhuhai United Laboratories Co., Ltd. Crystalline form of jak inhibitor and application thereof
WO2022161205A1 (zh) * 2021-01-29 2022-08-04 珠海联邦制药股份有限公司 一种含有jak抑制剂或其盐或其晶型的口服制剂及其制备方法和应用
WO2023239727A1 (en) * 2022-06-06 2023-12-14 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Lats inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
CN102105471A (zh) * 2008-07-25 2011-06-22 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的新化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007014619A (es) 2005-05-20 2009-02-13 Vertex Pharma Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
AU2006297351A1 (en) 2005-09-30 2007-04-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
BRPI0706537A2 (pt) 2006-01-17 2011-03-29 Vertex Pharma azaindóis úteis como inibidores de janus cinases
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
MX2008012860A (es) 2006-04-05 2009-01-07 Vertex Pharma Desazapurinas de utilidad como inhibidores de janus cinasas.
SI2288610T1 (sl) * 2008-03-11 2016-11-30 Incyte Holdings Corporation Derivati azetidina in ciklobutana kot inhibitorji jak
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
MX2011012961A (es) 2009-06-05 2012-01-30 Cephalon Inc Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina.
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
JP6600365B2 (ja) 2015-04-29 2019-10-30 无▲錫▼福祈制▲薬▼有限公司 Ｊａｋ阻害剤
JP6770580B2 (ja) * 2016-01-26 2020-10-14 杭州華東医薬集団生物医薬有限公司Ｈａｎｇｚｈｏｕ Ｈｕａｄｏｎｇ Ｍｅｄｉｃｉｎｅ Ｇｒｏｕｐ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ピロロピリミジン５員環アザ環状誘導体およびその利用
CN109843883B (zh) 2016-07-26 2022-01-14 苏州隆博泰药业有限公司 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
CN102105471A (zh) * 2008-07-25 2011-06-22 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的新化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTEL J. MENET ET AL.: ""Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634"", 《J. MED. CHEM.》 *

Also Published As

Publication number Publication date
JP6978097B2 (ja) 2021-12-08
EP3492469B1 (en) 2021-12-01
EP3492469A4 (en) 2019-10-09
US20190270740A1 (en) 2019-09-05
WO2018019223A1 (zh) 2018-02-01
EP3492468B1 (en) 2022-02-23
JP2019532913A (ja) 2019-11-14
KR102598246B1 (ko) 2023-11-02
KR20190034234A (ko) 2019-04-01
EP3492468A4 (en) 2020-03-04
KR102492378B1 (ko) 2023-01-27
JP2019532914A (ja) 2019-11-14
EP3492469A1 (en) 2019-06-05
WO2018019222A1 (zh) 2018-02-01
US11279699B2 (en) 2022-03-22
KR20190035755A (ko) 2019-04-03
US11414413B2 (en) 2022-08-16
EP3492468A1 (en) 2019-06-05
CN109790158A (zh) 2019-05-21
CN109843883B (zh) 2022-01-14
CN109790158B (zh) 2022-06-24
JP6978098B2 (ja) 2021-12-08
US20200190080A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
CN109843883A (zh) 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途
CA2602294C (en) Heterobicylic inhibitors of hvc
EA039357B1 (ru) Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка
US9346809B2 (en) Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors
JP2024037954A (ja) Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
US20070066632A1 (en) Fused bicyclic inhibitors of TGFbeta
US11564930B2 (en) RIP1 inhibitory compounds and methods for making and using the same
KR20160110518A (ko) 염증 질환의 치료를 위한 신규의 염 및 그의 약학 조성물
JP2005538992A (ja) キナーゼ阻害剤
EP2582703A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
JPWO2018097234A1 (ja) 新規オキソイソキノリン誘導体
US11572359B2 (en) PARP/PI3K double-target inhibit containing pyridopyrimidine structure
EA039344B1 (ru) Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
KR20210111313A (ko) 에이엘케이4/5 억제제인 융합된 고리 헤테로아릴 화합물
US20230310454A1 (en) Rip1 inhibitory compounds and methods for making and using the same
WO2021147790A1 (zh) 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途
CN111072655A (zh) 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190805

Address after: Room 745, 2 Blocks, Fenghua Commercial Plaza, Mudu Town, Wuzhong District, Suzhou City, Jiangsu Province

Applicant after: Suzhou Longbotai Pharmaceutical Co.,Ltd.

Address before: Room 219, second floor, A1 floor, Tianda Science Park, 80 Fourth Avenue, Jinshi Development Zone, 300457

Applicant before: TIANJIN LONGBOGEN PHARMACEUTICAL Co.,Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: 215126 Room 623, 6 storeys, 3 Block 118 Shengpu Road, Suzhou Industrial Park, Jiangsu Province

Applicant after: Suzhou Longbotai Pharmaceutical Co.,Ltd.

Address before: Room 745, 2 Blocks, Fenghua Commercial Plaza, Mudu Town, Wuzhong District, Suzhou City, Jiangsu Province

Applicant before: Suzhou Longbotai Pharmaceutical Co.,Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004454

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Yang Hengying

Inventor after: Kuang Sheng

Inventor after: Li Shiwei

Inventor after: Wu Kuiwang

Inventor after: Li Shuxin

Inventor before: Zhang Wenyan

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230714

Address after: 314000 301, Nanfang Building, Wangjiangjing Town, Xiuzhou District, Jiaxing, Zhejiang Province

Patentee after: Nuoxin Weikang (Jiaxing) Pharmaceutical Technology Co.,Ltd.

Address before: Room 623, 6 / F, building 3, 118 Shengpu Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee before: Suzhou Longbotai Pharmaceutical Co.,Ltd.

TR01 Transfer of patent right

Effective date of registration: 20230901

Address after: Room 623, 6 / F, building 3, 118 Shengpu Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee after: Suzhou Longbotai Pharmaceutical Co.,Ltd.

Address before: 314000 301, Nanfang Building, Wangjiangjing Town, Xiuzhou District, Jiaxing, Zhejiang Province

Patentee before: Nuoxin Weikang (Jiaxing) Pharmaceutical Technology Co.,Ltd.

TR01 Transfer of patent right